Information Provided By:
Fly News Breaks for June 4, 2018
AGIO
Jun 4, 2018 | 11:37 EDT
JPMorgan analyst Anupam Rama said updates from the phase 1b trial center on the ivosidenib combination arm includes an incremental increase in ORR and in-line CR rates with larger patient dataset, which reinforces his view of the potential for meaningful additive benefit from IDH inhibition on top of azacitidine. Rama added that he did not see any major incremental safety concerns in the data. Rama has an Overweight rating on Agios shares, which are down nearly 11% in morning trading.
News For AGIO From the Last 2 Days
There are no results for your query AGIO